We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma (STORM)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01653067
First Posted: July 30, 2012
Last Update Posted: October 27, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Johannes Gutenberg University Mainz
Technische Universität München
Ludwig-Maximilians - University of Munich
University Hospital Ulm
University Hospital Erlangen
Charite University, Berlin, Germany
University Hospital Freiburg
Johann Wolfgang Goethe University Hospital
Information provided by (Responsible Party):
Mathias Witzens-Harig, University Hospital Heidelberg
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2018
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):